Bolt Biotherapeutics SEC filings document the company’s public-company governance, financial-results reporting, and clinical-stage oncology disclosures. Recent Form 8-K reports furnish quarterly and annual results and business updates for BDC-4182 and the Boltbody™ ISAC platform, while proxy materials describe director elections, auditor ratification, and stockholder meeting mechanics.
The filing record also includes emerging growth company status, restructuring disclosures under exit or disposal activity rules, estimated severance and benefit costs, and updates on pipeline and capital-preservation measures. These filings frame Bolt’s governance procedures, operating expense controls, reporting status, and development-stage business disclosures as a Nasdaq-listed biopharmaceutical issuer.
Sheila Gujrathi, Bolt Biotherapeutics' Chief Strategy Officer and a director, reported direct receipt of 72,766 common shares and 2,763.833 Series D Preferred shares when her Prana Therapies shares converted at the merger closing on October 23, 2026. SilverArc Private Fund I, L.P.'s Prana holdings converted into 13,055 common shares and 495.874 Series D Preferred shares; Gujrathi disclaims beneficial ownership of the fund's securities except to the extent of any pecuniary interest. Each Series D Preferred share is convertible into 1,000 common shares, subject to conditions including requisite stockholder approval.
Bolt Biotherapeutics, Inc. identifies Sheila Gujrathi as a director and Chief Strategy Officer.
Bolt Biotherapeutics, Inc. (BOLT) completed its acquisition of Prana Therapies on October 23, 2026, in a stock-for-stock merger, issuing 430,746 common shares and 16,360.929 Series D preferred shares; each preferred share converts into 1,000 common shares, subject to stockholder approval and other conditions. Sheila Gujrathi was appointed chief strategy officer and a Class II director.
Bolt agreed to sell 13,995.311 Series D preferred shares for $120 million in upfront gross proceeds; the financing was expected to close October 26, 2026, subject to customary conditions. Warrants could provide approximately $60 million in additional gross proceeds if exercised in full for cash. After financing and full preferred conversion, projected fully diluted ownership is 6.9% for pre-transaction Bolt holders, 51.7% for former Prana holders and 41.4% for investors, without giving effect to beneficial ownership limitations.
In the BDC-4182 Phase 1 study, 25 subjects had received treatment across four dose levels as of October 1, 2026; the every-two-week step-up cohorts had a 53% disease control rate, with 8 of 15 evaluable patients showing stable disease as their best overall response. The study reported mostly Grade 1/2 immune-related adverse events and no dose-limiting toxicities. The transaction triggers a $4.5 million lease termination payment.
Bolt Biotherapeutics, Inc. (BOLT) amended its lease for its Redwood City office, laboratory and vivarium facilities. On October 1, 2026, the company paid the landlord $1.0 million and acknowledged the landlord’s right to draw the existing $1.5 million letter of credit in its entirety. The parties set an accelerated lease expiration date of December 31, 2027, or earlier following the closing of a financing or other strategic transaction. Upon closing of such a transaction, BOLT will pay an additional $4.5 million termination payment.
Effective October 1, 2026, BOLT’s ongoing rent and operating expense obligations for the premises are not significant. The company will maintain its existing sublease arrangements and remit to the landlord 100% of sublease rent and common area maintenance payments received from each subtenant. BOLT is evaluating the accounting effects of the amendment.
Bolt Biotherapeutics, Inc. (BOLT) reported that Chief Operating Officer Grant Yonehiro sold a total of 13,176 shares of Common Stock in three transactions on September 16–18, 2026. The company states these sales were made to cover tax withholding obligations arising from the vesting of restricted stock units granted on October 22, 2025.
The transactions were open-market or private sales at weighted average prices of $3.7740, $3.3183, and $3.2364 per share, with actual prices in specified ranges. No Rule 10b5-1 trading plan is reported, and resulting share holdings are not stated in this filing.
Bolt Biotherapeutics, Inc. (BOLT) reported that Sarah Nemec, Senior VP, Finance and PAO, purchased 509 shares of common stock on June 5, 2026 at $3.876 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). She later sold 843 shares on September 16, 2,922 shares on September 17, and 4,077 shares on September 18, 2026 at weighted average prices of $3.774, $3.3183 and $3.2364 per share, respectively, to cover tax withholding obligations arising from the vesting of restricted stock units granted on October 22, 2025. No Rule 10b5-1 trading plan is reported.
Bolt Biotherapeutics, Inc. (BOLT) reported that President, CEO and CFO William P. Quinn sold company common stock on three days in September 2026 and made one earlier purchase in June 2026. The September sales, totaling 17,566 shares, were made at weighted average prices and, per footnotes, were to cover tax withholding obligations upon vesting of restricted stock units granted on October 22, 2025. On June 5, 2026, he acquired 637 shares through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). No Rule 10b5-1 trading plan is reported.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of Bolt Biotherapeutics, Inc. Both entities are organized in Delaware and list 520 Madison Avenue, New York, NY 10022 as their principal business office.
The filing states beneficial ownership of 98,625 shares of Bolt Biotherapeutics common stock, representing 5.13% of the class. The reporting persons have sole voting power and sole dispositive power over all 98,625 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.
Bolt Biotherapeutics, Inc., a clinical-stage oncology company, reported a Q2 2026 net loss of $7.7 million and a six‑month net loss of $15.0 million, both narrower than in 2025 due to a major October 2025 restructuring that cut headcount by about 50% and lowered research and development and general and administrative expenses. Collaboration revenue fell sharply to $5,000 in Q2 and $31,000 for the first half, from $1.8 million and $3.0 million a year earlier, reflecting limited current collaboration activity with Toray and Genmab.
Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026. Management states this may fund operations only into the first quarter of 2027 and concludes there is substantial doubt about the company’s ability to continue as a going concern without additional capital. An $0.8 million non‑cash impairment charge was recorded on right‑of‑use assets after a sublessee gave termination notice on part of the main facility. The company continues to advance its lead ISAC candidate BDC‑4182 in an ongoing Phase 1/2 trial in gastric and gastroesophageal junction cancer.
Bolt Biotherapeutics reported second quarter 2026 results while emphasizing progress in its lead oncology program. The Phase 1/2 trial of BDC-4182, a first-in-class immune-stimulating antibody conjugate targeting claudin 18.2, is ongoing in gastric and gastroesophageal cancers, with patients now being treated in Cohort 4 at the 4.0 mg/kg dose level. Initial clinical data are expected to be released with the company’s third quarter 2026 results.
Financially, collaboration revenue for the quarter was $5,000 versus $1.8 million a year earlier, reflecting a sharp decline in R&D collaboration activity. Operating discipline offset some of this impact: R&D expenses fell to $5.1 million from $7.5 million and G&A to $2.4 million from $3.5 million, aided by prior restructuring. Net loss for the quarter narrowed to $7.7 million from $8.6 million, and for the first half of 2026 to $15.0 million from $19.6 million. Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026, which the company expects will fund operations into the first quarter of 2027, while the rest of its pipeline remains on hold pending further progress and partnering.